<DOC>
	<DOCNO>NCT00873392</DOCNO>
	<brief_summary>Medical treatment idiopathic Parkinson disease motor symptom require dopaminergic drug , long term disable side effect . ( fluctuation , dyskinesia , ON/OFF phenomenon ) . Use nicotine Parkinson 's disease suggest low prevalence smoker among Parkinsonian patient . However , control study provide conflict result . One patient show substantial decrease parkinsonian symptom transdermal nicotine-therapy . Currently , patient treat since 8 year excellent safety , especially cardiovascular level . Otherwise , investigator perform open pilot safety feasibility study 6 patient , demonstrate possibility control study . In study , patient receive daily dos several month 105 mg/day could , parallel , decrease L-Dopa agonist dos , improve motor score . The investigator propose phase II , control , single blind randomise efficacy study ( n=40 ) 2 parallel group . ( 1 group transdermal nicotine-therapy / 1 control group without additional therapy ) The main objective verify correlation UPDRS ( score III ) motor score administrate nicotine dose . This study also allow evaluation nicotine neuroprotective effect . The incrementation phase weekly step 5 mg 20 mg , 10 mg reach 90 mg/j maximal tolerate dose , last 11 week follow 28 week phase stable dose . After maximal dose `` plateau phase '' , treatment progressively decrease 15 mg weekly step , de 6-week period follow five-week wash phase . Taking account result pilot study , long-term high dos treatment , seem liable improve patient deeply suffer disease . This investigator propose monocentric institutional project .</brief_summary>
	<brief_title>Efficacy Transdermal Nicotine , Motor Symptoms Advanced Parkinson 's Disease</brief_title>
	<detailed_description>Experimental plan Phase II control study , 40 patient , randomise single blind , 2 group : - One group treat transdermal nicotine-therapy ( N= 20 ) , - One group without additional therapy ( N= 20 ) . This study consist : - One phase weekly incrementations dose 11 week , - Steps 5 mg 20 mg - Then step 10 mg dose 90mg maximal tolerate dose - One stable dose phase , ( 90 mg maximal tolerate dose ) 28 week , - One phase decrementing : treatment progressively decrease 6 week period ,</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Patients idiopathic Parkinson 's disease accord United Kingdom Parkinson 's Disease Society Brain Bank ( UKPDSBB ) , since least three year , treat Ldopa 2 year minimum motor fluctuation ( amendment 12/10/2010 ) Patients age 35 70 year inclusive , LDopa responder : LDopa test improvement 30 % UPDRSIII motor score , LDopa treatment since least three year , Patients Parkinson 's disease stage maximum IV ( `` OFF '' state ) accord modify Hoehn Yahr classification ( without treatment since least 12 hour ) , III maximum `` ON '' state , Non smoker , Signed Informed Consent Previous neurosurgery Parkinson 's disease , Weight &lt; 45 kg &gt; 100 kg , Previous Parkinson 's disease treatment transdermal nicotinetherapy discontinue less 6 month inclusion , History allergy Nicotine , History allergy transdermal device , Cutaneous disorder wich could disturb use transdermal device , Cognitive disorder , ( Mattis score &lt; 125 ) History detection inclusion cardiac arrhythmia , History coronary failure , History cardiac failure , ( NYHA II IV &amp; ejection fraction ( EF ) &lt; 40 % ) Severe arterial hypertension ( diastolic &gt; 100 mmHg ) uncontrolled , Symptomatic orthostatic hypotension , ( 2 point differential stand position systolic &lt; 100mm Hg clinical evidence ) History stroke occlusive peripheral vascular disease , History hyperthyroid , History detection inclusion type I II diabetes , ( HbA1c &lt; 11 % ) History pulmonary disease : asthma , chronic obstructive pulmonary disease ( COPD ) , History autoimmune disease , Progressive depression , suicide attack , acute psychosis , invasive hallucination , psychiatrist opinion harmful correct compliance experimentation , History recent gastroduodenal ulcer , ( &lt; 3 month ) History detection inclusion hepatobiliary renal failure , ( clearance &lt; 60 mL/min ) Pregnancy , breastfeeding , Absence effective contraception woman childbearing potential , Treatment nifedipine , betablockers , diuretic , insulin H2 antihistaminics potential side effect combination nicotine , Patients unlikely compliant fully cooperate study .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Motor fluctuation</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Drug treatment</keyword>
	<keyword>neuroprotection</keyword>
</DOC>